Belimumab, a B lymphocyte stimulator (BLyS) inhibitor, recently approved for patients with active, autoantibody-positive systemic lupus erythematosus (SLE) has paved the way for newer drugs that could arrest the complex autoimmune process and reverse the disease pathology. However, there is a need to further delineate long term effects of belimumab on disease activity and progression in patients with lupus nephritis, pregnancy and paediatric populations. Here, we review the on-going clinical trials and registry studies of belimumab in different populations that could define its role in the SLE armamentarium.
CD Tripathi and Preeta Kaur Chugh
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : April 18, 2019